<SEC-DOCUMENT>0001062993-15-001619.txt : 20150330
<SEC-HEADER>0001062993-15-001619.hdr.sgml : 20150330
<ACCEPTANCE-DATETIME>20150330171751
ACCESSION NUMBER:		0001062993-15-001619
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150327
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150330
DATE AS OF CHANGE:		20150330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51652
		FILM NUMBER:		15735467

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>

<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp.: Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT></B><BR>Washington, D.C.
20549<B> </B><BR></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center>Current Report<BR>Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934<BR></P>
<P align=center>Date of Report (Date of earliest event reported): <B><U>March
26, 2015 </U></B></P>
<P align=center><B><U><FONT size=5>ANAVEX LIFE SCIENCES CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter)<BR></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-51652 </U></B></TD>
    <TD align=center width="33%"><B><U>98-0608404 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction </TD>
    <TD align=center width="33%">(Commission </TD>
    <TD align=center width="33%">(IRS Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>of incorporation) </TD>
    <TD align=center width="33%">File Number) </TD>
    <TD align=center width="33%">Identification No.) </TD></TR></TABLE>
<P align=center><B><U>51 West 52nd Street, 7th Floor, New York, NY USA 10019
</U></B><BR>(Address of principal executive offices) (Zip Code)<BR></P>
<P align=center>Registrant's telephone number, including area code
<B><U>1-844-689-3939 </U></B></P>
<P align=center><B><U>Not Applicable </U></B><BR>(Former name or former address,
if changed since last report.) <BR></P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below): </P>
<P align=justify>[&nbsp;&nbsp; ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)</P>
<P align=justify>[&nbsp;&nbsp; ] Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a -12)</P>
<P align=justify>[&nbsp;&nbsp; ] Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</P>
<P align=justify>[&nbsp;&nbsp; ] Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) </P>
<P align=center>1 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Item 5.03.</B> </TD>
    <TD align=left width="90%"><B>Amendment to Articles of Incorporation or
      Bylaws; Change in Fiscal Year.</B> </TD></TR></TABLE>
<P align=justify style="text-indent: 5%">On March 26, 2015, Anavex Life Sciences Corp., a Nevada
corporation (the &#147;<U>Company</U>&#148;), held a special meeting of stockholders (the
&#147;<U>Meeting</U>&#148;) as prescribed in the Proxy Statement filed by the Company with
the SEC on February 13, 2015. At the Meeting, as described under <U>Item
5.07</U> below, the stockholders of the Company approved an amendment to the
Company&#146;s Articles of Incorporation to increase the Company&#146;s authorized common
stock, par value $0.001 per share (&#147;<U>Common Stock</U>&#148;), from 150,000,000 to
400,000,000 shares, which amendment became effective upon the filing of a
Certificate of Amendment (&#147;<U>Amendment</U>&#148;) with the Secretary of State of
Nevada on March 27, 2015.</P>
<P align=justify style="text-indent: 5%">The Amendment is attached and filed as <U>Exhibit 3.1</U> to
this Current Report on Form 8-K and is incorporated by reference herein.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Item 5.07.</B> </TD>
    <TD align=left width="90%"><B>Submission of Matters to a Vote of Security
      Holders.</B> </TD></TR></TABLE>
<P align=justify>At the Meeting, six (6) proposals were submitted for a vote of
the Company&#146;s stockholders and the related results are as follows: </P>
<P align=justify><I><U>Proposal No. 1</U></I><I>: The election of Christopher
Missling, Ph.D., Athanasios Skarpelos, Bernd Metzner, Ph.D. and Elliot Favus,
M.D. for terms until the next annual meeting of stockholders or until each such
director&#146;s successor shall have been duly elected and qualified</I>. The
stockholders elected each of the four (4) directors by the following votes: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><U>Director</U> </TD>
    <TD align=center width="25%"><U>Votes For</U> </TD>
    <TD align=center width="25%"><U>Votes Withheld</U> </TD>
    <TD align=right width="25%"><U>Broker Non-Votes</U> </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Christopher Missling, Ph.D. </TD>
    <TD align=center width="25%" bgColor=#e6efff>18,230,254 </TD>
    <TD align=center width="25%" bgColor=#e6efff>308,051 </TD>
    <TD align=right width="25%" bgColor=#e6efff>16,346,920 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Athanasios Skarpelos </TD>
    <TD align=center width="25%">18,238,211 </TD>
    <TD align=center width="25%">300,094 </TD>
    <TD align=right width="25%">16,346,920 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Bernd Metzner, Ph.D. </TD>
    <TD align=center width="25%" bgColor=#e6efff>18,358,531 </TD>
    <TD align=center width="25%" bgColor=#e6efff>179,774 </TD>
    <TD align=right width="25%" bgColor=#e6efff>16,346,920 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Elliot Favus, M.D. </TD>
    <TD align=center width="25%">15,532,631 </TD>
    <TD align=center width="25%">3,005,674 </TD>
    <TD align=right width="25%">16,346,920 </TD></TR></TABLE>
<P align=justify><I><U>Proposal No. 2</U></I><I>: The approval of a non-binding
advisory resolution approving the compensation of the Company&#146;s named executive
officers, as described in the &#147;Executive and Director Compensation&#148; section and
compensation tables and narrative disclosure of the Company&#146;s Proxy
Statement.</I> The stockholders approved the non-binding advisory resolution on
executive compensation by the following votes: </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left>Votes For </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">17,485,200 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Votes Against </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">719,705 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Abstentions </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">333,400 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Broker Non-Votes </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">16,346,920 </TD></TR></TABLE></DIV>
<P align=justify><I><U>Proposal No. 3</U></I><I>: The approval of a non-binding
resolution regarding the frequency of future advisory votes on the compensation
of the Company&#146;s named executive officers which could be held every year, every
two (2) years or every three (3) years. </I>The stockholders approved the
non-binding advisory resolution regarding the frequency of future votes on
executive compensation with respect to every three (3) years as follows: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left>1 Year </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">5,178,888 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>2 Years </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">1,064,988 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>3 Years </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">12,199,552 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Abstentions </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">94,877 </TD></TR></TABLE>
<P align=justify>The Company has decided to set the frequency of future advisory
votes on the compensation of the Company&#146;s named executive officers at every
three (3) years going forward. </P>
<P align=justify><I><U>Proposal No. 4</U></I><I>:</I> The stockholders ratified
BDO USA, LLP as the Company&#146;s independent registered public accounting firm by
the following votes: </P>
<P align=center>2 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_3></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left>Votes For </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">34,446,371 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Votes Against </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">277,823 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Abstentions </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">161,031 </TD></TR></TABLE>
<P align=justify><I><U>Proposal No. 5</U></I><I>: Charter amendment to increase
the amount of shares of authorized Common Stock</I>. The stockholders authorized
the amendment of the Company&#146;s Articles of Incorporation to increase the
Company&#146;s authorized Common Stock from 150,000,000 to 400,000,000 shares as
follows:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left>Votes For </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">28,989,615 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Votes Against </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">4,674,450 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Abstentions </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">1,221,160 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Broker Non-Votes </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">0 </TD></TR></TABLE>
<P align=justify><I><U>Proposal No. 6</U></I><I>: Regarding a vote to amend the
Company&#146;s Articles of Incorporation to authorize up to 10,000,000 shares of
preferred stock of the Company, par value $0.001 per share.</I> The stockholders
did not submit enough affirmative votes to approve the amendment of the
Company&#146;s Articles of Incorporation as set forth in the proposal with respect to
authorizing 10,000,000 shares of blank-check preferred stock of the Company:
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left>Votes For </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">13,301,577 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Votes Against </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">4,862,479 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Abstentions </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">374,249 </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left>Broker Non-Votes </TD>
    <TD noWrap align=left width="85%">
    <p style="margin-left: 10">16,346,920 </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Item 9.01.</B> </TD>
    <TD align=left width="90%"><B>Financial Statements and Exhibits.</B>
  </TD></TR></TABLE>
<P align=justify><I><U>(d) Exhibits</U></I><I> </I></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%" bgColor=#eeeeee><a href="exhibit3-1.htm">3.1. </a> </TD>
    <TD bgColor=#eeeeee>
      <P align=justify><a href="exhibit3-1.htm">Certificate of Amendment to the Articles of
      Incorporation</a></P></TD></TR></TABLE>
<P align=center>3</P>
<P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>

<P></P><!--$$/page=--><A name=page_4></A>
<P align=center><B><U>SIGNATURES</U></B></P>
<P align=justify style="text-indent: 5%">Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P style="MARGIN-LEFT: 50%" align=justify><B>ANAVEX LIFE SCIENCES CORP. </B></P>
<P style="MARGIN-LEFT: 50%" align=justify><I><U>/s/ Christopher
Missling</U></I><BR>Name: Christopher Missling, Ph.D.<BR>Title: Chief Executive
Officer <BR>Date: March 30, 2015<BR></P>
<P align=center>4 </P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>exhibit3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp. - Exhibit 3.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right><IMG src="exhibit3-1x1x1.jpg" border=0></P><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><IMG src="exhibit3-1x1x2.jpg" border=0></TD>
    <TD align=left width="90%"><B>BARBARA K. CEGAVSKE </B><BR>
      <B>Secretary of
      State </B><BR><B>202 North Carson Street </B><BR><B>Carson City, Nevada
      89701-4201 </B><BR><B>(775) 684-5708 </B><BR><B>Website: www.nvsos.gov
    </B></TD></TR></TABLE><BR>
<DIV align=left>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=6 width="50%" border=1>

  <TR vAlign=top>
    <TD align=center><B><FONT size=5>Certificate of Amendment
      </FONT></B><BR>(PURSUANT TO NRS 78.385 AND 78.390)
</TD></TR></TABLE></DIV><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>USE BLACK INK ONLY - DO NOT HIGHLIGHT </B></TD>
    <TD align=right width="50%"><B>ABOVE SPACE IS FOR OFFICE USE ONLY
  </B></TD></TR></TABLE>
<P align=center><B><U>Certificate of Amendment to Articles of
Incorporation</U></B><BR><B><U>For Nevada Profit
Corporations</U></B><BR><B>(Pursuant to NRS 78.385 and 78.390 - After Issuance
of Stock)</B><BR></P>
<P align=justify>1. Name of corporation:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#DDE4FF>
      <P>Anavex Life Sciences Corp. <BR></P>
      <P>&nbsp;</P></TD></TR></TABLE>
<P align=justify>2. The articles have been amended as follows: (provide article
numbers, if available)</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgcolor="#DDE4FF">
      <P>Article 3 of the Articles of Incorporation of Anavex Life Sciences
      Corp. is hereby amended to read as follows: <BR><BR>Article 3. Shares:
      Number of shares with par value: 400,000,000 Par value: $0.001 Number of
      shares without par value: None </P>
      <P>&nbsp;</P></TD></TR></TABLE>
<br>
<TABLE width="100%" border=0 cellPadding=0
cellSpacing=0
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; ">
  <TR vAlign=top>
    <TD colspan="5" align=left>3. The vote by which the stockholders holding shares in the
corporation entitling them to exercise at least a majority of the voting power,
or such greater proportion of the voting power as may be required in the case of
a vote by classes or series, or as may be required by the provisions of the
articles of incorporation* have voted in favor of the amendment is: </TD>
  </TR>
  <TR vAlign=top>
    <TD width="92%" align=left>&nbsp;</TD>
    <TD width="8%" colspan="4" align=center bgcolor="#DDE4FF">majority</TD>
  </TR>
</TABLE>
<br>

<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>4. Effective date and time of filing:
      (optional)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD width="7%" align=left> Date: &nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD width="25%" align=left bgcolor="#DDE4FF"></TD>
    <TD align=left width="7%">&nbsp;&nbsp;&nbsp;&nbsp; Time: </TD>
    <TD
      width="25%" align=left bgcolor="#DDE4FF">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD colspan="4" align=center>&nbsp;(must not be later than 90 days after the
    certificate is filed) </TD>
    </TR></TABLE>
<P align=justify>5. Signature: (required)</P>
<P align=justify><B><U><FONT
size=4>X &nbsp;/s/ for Christopher Missling, PhD.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></U></B><BR><B>Signature
of Officer</B><BR></P>
<P align=justify>*If any proposed amendment would alter or change any preference
or any relative or other right given to any class or series of outstanding
shares, then the amendment must be approved by the vote, in addition to the
affirmative vote otherwise required, of the holders of shares representing a
majority of the voting power of each class or series affected by the amendment
regardless to limitations or restrictions on the voting power thereof.</P>
<P align=justify><B>IMPORTANT:</B><B> </B>Failure to include any of the above
information and submit with the proper fees may cause this filing to be
rejected.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=right width="50%">Nevada Secretary of State Amend Profit-After
    </TD></TR>
  <TR vAlign=top>
    <TD align=left><I>This form must be accompanied by appropriate fees.
    </I></TD>
    <TD align=right width="50%">Revised: 1-5-15 </TD></TR></TABLE><BR>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=6 width="12%" border=1>

  <TR vAlign=top>
    <TD align=center bgcolor="#FFFFAA"><B>Reset </B></TD>
  </TR></TABLE></DIV><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exhibit3-1x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit3-1x1x1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#`!`+#`X,"A`.#0X2$1`3&"@:&!86
M&#$C)1TH.C,]/#DS.#=`2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!#`1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P``1"`!#`.0#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#T"BBJ5]?_
M`&.ZLH?*W_:I3'G=C;\I.>G/2@"[16-J>O?V?-?1_9O,^R6JW&?,QNR2,=..
MG6LB7QSY>@P:I_9V?-G:+R_/Z8&<YV_TH`["BN<M_%/GZ<UW]CV[98(]OFY_
MU@4YSCMN_'%:%EJWVJ'49/(V?8IY(<;\[]H!STXSGWH`TZ*X^W\<^=H=WJ7]
MG;?L\B)Y?GYW;N^=O'Y58L?%_P!LTVYN_L.SR+;[1L\[.[YF7&=O^SU]Z`.H
MHKFI/%FSQ-#H_P!BSYNS][YO3<N[IC^M7=3UW^S[B\B^S>9]FLQ=9WXW?,1M
MZ<=.M`&Q17+Z%XO_`+895^P^3D2G_7;ON!3_`'1UW?I5[2]>_M"[M8/LWE_:
M++[7N\S.WY@NWISUZT`;5%<Y'XJ\SQ'<Z1]BQY"N?-\W[VT9Z8_K5+2/'/\`
M:<@3^SO*S(J9\_=U5VS]W_8_6@#L**Y.[\:_9GTQ?[/W?;XDDSYV-FXXQ]WG
M]*W+W4OLFH6MIY._[1'*^[=C;L`.,8YSF@#0HKDK#QM]MUJUT[^S]GGJC>9Y
MV=NY`W3;SUQ6C;>(?M%U90?9=OVJ>>'=YF=OEYYZ<YQ^'O0!N45SU[XG^R>)
MX-&^Q[_.V_OO-QC/^SC^M4(/'7FZC<6G]G8\EPF[S^O[Q4Z;?]K/X4`=A16'
M/XA\FY>'[+G9?16>?,Z[P#NZ=L]/UJ'Q+XI_L"[MH/L?VCSQG=YNW;SCT-`'
M145RFM^-/[(FEC_L_P`[RYC%GSMN<*K9^Z?[WZ5MVFI_:=2DM/)V[((YM^[.
M=V>,8[8H`T**Y;4_&/\`9^GBZ^P>9FZDM]OG8^X<9SM[^E)?^,OL>JV=C]@W
M_:4B;?YV-N_VV\XH`ZJBJFE7O]HZ9;7GE^7YZ!]F[.W/;-6Z`"BBB@`K%US_
M`)">B?\`7V?_`$6U;58NN?\`(3T3_K[/_HMJ`,?Q-_Q]ZY_V#$_]#:N2NO\`
MD0K'_K]?_P!!KK?$W_'WKG_8,3_T-JY*Z_Y$*Q_Z_7_]!H`VM._Y%Z7_`*^;
M+_T"*N@T;_CT\1?]?T__`*`M<_IW_(O2_P#7S9?^@15T&C?\>GB+_K^G_P#0
M%H`X73_^1'U;_KXAK0T+_D7-2_[!A_\`1LM9^G_\B/JW_7Q#6AH7_(N:E_V#
M#_Z-EH`FG_Y*79_2+_T6*V?$W_'_`*O_`-@@?^C&K&G_`.2EV?TB_P#18K9\
M3?\`'_J__8('_HQJ`,#P+_K8_P#=N?\`T&*MSPO_`,A;2O\`L"_^U!6'X%_U
ML?\`NW/_`*#%6YX7_P"0MI7_`&!?_:@H`S+;_DH^I?[DO_H%8WA+_CY7_KX3
M_P!%RULVW_)1]2_W)?\`T"L;PE_Q\K_U\)_Z+EH`FU;_`%_AG_KUA_\`0S7=
M:U_R,.E_]>]U_P"@K7"ZM_K_``S_`->L/_H9KNM:_P"1ATO_`*][K_T%:`.$
MT'_D=-,_ZYP_^B171Z9_R%=&_P"OZ^_DU<YH/_(Z:9_USA_]$BNCTS_D*Z-_
MU_7W\FH`JZU_R4^P_P"V?]:P++_D8M0_Z[#_`-*(ZW]:_P"2GV'_`&S_`*U@
M67_(Q:A_UV'_`*41T`=3??\`(1G_`.P[;?\`H(JE\2O^0MIG^X?_`$(5=OO^
M0C/_`-AVV_\`015+XE?\A;3/]P_^A"@#-\;_`/'Y<_\`7ZW_`*+CKM]*_P"1
MCN?^O&W_`)M7$>-_^/RY_P"OUO\`T7'7;Z5_R,=S_P!>-O\`S:@#C/$__(OI
M_P!A.X_]"--U[_D:M'_ZXVW\Z=XG_P"1?3_L)W'_`*$:;KW_`"-6C_\`7&V_
MG0!WWA7_`)%G3O\`K@M:U9/A7_D6=._ZX+6M0`4444`%8NN?\A/1/^OL_P#H
MMJVJI7UA]LNK*;S=GV64R8VYW?*1CKQUH`YKQ-_Q]ZY_V#$_]#:N2NO^1"L?
M^OU__0:]&U/0?[0FOI/M/E_:[5;?'EYVX).>O/7I61+X&\S08-+_`+1QY4[2
M^9Y'7(QC&[^M`&5IW_(O2_\`7S9?^@15T&C?\>GB+_K^G_\`0%IUOX6\C3FM
M/MF[=+!)N\K'^K"C&,]]OX9K0LM)^RPZC'Y^_P"VSR39V8V;@!CKSC'M0!YG
MI_\`R(^K?]?$-:&A?\BYJ7_8,/\`Z-EK?M_`WDZ'=Z;_`&CN^T2(_F>1C;M[
M8W<_G5BQ\(?8]-N;3[=O\^V^S[_)QM^9FSC=_M=/:@#GI_\`DI=G](O_`$6*
MV?$W_'_J_P#V"!_Z,:K<GA/?XFAUC[;CRMG[KRNNU=O7/]*NZGH7]H7%Y+]I
M\O[39BUQLSM^8G=UYZ]*`.(\"_ZV/_=N?_08JW/"_P#R%M*_[`O_`+4%6]"\
M(?V.RM]N\[`E'^IV_?"C^\>FW]:O:7H/]GW=K/\`:?,^SV7V3;Y>-WS!MW7C
MITH`Y.V_Y*/J7^Y+_P"@5C>$O^/E?^OA/_1<M=Y'X5\OQ'<ZO]MSYZN/*\K[
MNX8ZY_I5+2/`W]F2!_[1\W$BOCR-O177'WO]O]*`.6U;_7^&?^O6'_T,UW6M
M?\C#I?\`U[W7_H*U2N_!7VE],;^T-OV")(\>3G?M.<_>X_6MR]TW[7J%K=^=
ML^SQRIMVYW;P!G.>,8H`\UT'_D=-,_ZYP_\`HD5T>F?\A71O^OZ^_DU6K#P3
M]BUJUU'^T-_D*B^7Y.-VU`O7=QTS6C;>'OL]U93_`&K=]EGGFV^7C=YF>.O&
M,_C[4`<UK7_)3[#_`+9_UK`LO^1BU#_KL/\`THCKO[WPQ]K\3P:S]LV>3M_<
M^5G./]K/]*H0>!?*U&XN_P"T<^<X?;Y'3]XK]=W^SC\:`(+[_D(S_P#8=MO_
M`$$52^)7_(6TS_</_H0KJ)_#WG7+S?:L;[Z*\QY?38`-O7OCK^E0^)?"W]OW
M=M/]L^S^0,;?*W;N<^HH`XOQO_Q^7/\`U^M_Z+CKM]*_Y&.Y_P"O&W_FU4];
M\%_VO-+)_:'D^9,9<>3NQE57'WA_=_6MNTTS[-J4EWYV[?!'#LVXQMSSG/?-
M`'GOB?\`Y%]/^PG<?^A&FZ]_R-6C_P#7&V_G75ZGX._M#3Q:_;_+Q=27&[R<
M_?.<8W=O6DO_``;]LU6SOOM^S[,D2[/)SNV>^[C-`&IX5_Y%G3O^N"UK54TJ
MR_L[3+:S\SS/(0)OVXW8[XJW0`4444`%%%%`!1110`4444`%%%%`!1110`5G
M7.H30ZK#:K;EHG0LTG/'/T_Q]\=]&DH`P1K=Q]F@FD-O#'=HDD4KJ=L*M_?^
M;GL,@CEO;E\6LSR(DX2+R%>.*3`)+,[[,J<\`$@]\@]L<VXM(CA1DAN;B,8"
M+M*_)&/X%XX'OU]^!3FTFV,L;+O2-`G[I<;"4.4)&.H/I^.<"@"L]]J$5T]H
MXMS)(R"&54;8N[<2K#=DD!,]1G(Z4JZM(S6""-2T\YAF/92%<\?BGY?6IETH
M['5[^ZD8N'1V$8,;>HPHSZ<YXXIK:!IK26TK6T9EMW#B0HI9R`1\QQD]<_4"
M@!^FW\UY-<I-;F(1,`IY^;CW'^!]AWT***`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
7`HHHH`****`"BBB@`HHHH`****`/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>exhibit3-1x1x2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit3-1x1x2.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#`!`+#`X,"A`.#0X2$1`3&"@:&!86
M&#$C)1TH.C,]/#DS.#=`2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!#`1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P``1"`!I`&T#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#T"BBB@`HH
MHH`**KW=[;64>^ZG2)>VX\GZ#O6#=^,[2,[;2"2<_P!YOW:_KS^E-)O8#IJ*
MXE_&E\Q^2U@0>^YO\*6/QG>J?WMI`X]BR?XU7LY`=K17.6?C"QF.VYCDMSZX
MWK^8Y_2MZWN8+J,26\J2H?XD;(J6FMP):***0!1110`4444`%<OKGBI8&>VT
MW;)*.&F/*J?0#N?T^M-\6:X8LZ=:.0Y'[YU/W0?X1[^OI^-<TD`BC994V$CB
M0\J/;C^E;4Z?-JQ-B_9I[F43W#2.TIY<Y.2>F6],_E32((MZOA0W*8Y9>O7_
M``]Q5?S'9=B83*DJQ&-V.P/>KUOHTUT,^7Y,;(`3-RP;N0!_6M^9+X27YE2>
MZBD(8%BP50<^P`J=;^$S,Y!!+^8!_=X.`/;D?@*VH]!1PZM/*2Z!&V!5!`Z<
M8]JEG\,"82'[3*&=`A+X;@8QV]A4NJ]FPW.=3;=7"J%XZ<'D#U)_STI\!GM9
M1=6,KH0V%/\`$P`R<CH0/>I]1T.[LUDD\CS!@!#`<!<=20>>?:JL<[(QCE;?
M",1F5`<8ZX'^<T^:,MQG8Z%XFCU!UMKI5AN2/E(/RR'V]#[5T%>77(5Y,1H`
MPQ]PY'`'3'\Z[#POKAOHS:7;YNHQE6/_`"T7_$=_PK&I3<=1IG0T445B,*IZ
MK>KIVG37+8RBX4'NQX`_/%7*Y'QS='=:V:GCF5A^B_\`LU5%7=@.<MT#[Y9V
M;YR0'(SDG))/N?7ZU%<.&^564K&`2&;!;GD#\S^%6I&>"V8!MN/EY0JV/J.H
MZ]:32;9+B\A!>.1`0Q^7!!/\)/?&*ZJDN2-B5JRWH*0-<RJ<M)#R@+9$>2<@
M?3CFN@49/TJ673;=C]LCC6.50$8KD97I_A3O*A&3Y8;CH<D`?XUBJNA,H798
MMD!&5((]0:M@#%4'F;.8@B\8=R25^H]_?^=2BXA5ALE$IQR)../7/05E)MZE
MI6+#IE3ZURFN:4CLUS$FYU)+Q!L+)QU^M=%.28P8Y`1NY*-D*/3'>J;E1&WF
MAG;L4;G\O_KU<));BDG?0XFTD,<GE920NN!AL#D$8)/UJ1I'M[B*Z@E7S4;=
MD=`P_H>GYT_5H4AFDVN$C8F1`$R6;C(SZ=Z50;F$*$10PR6PN6;T'3CZ5T0:
ME&P;'HUE<I>6<-S']V5`P]O:IZY?P/=F2TN+1C_J6#I[!LY'Y@G\:ZBN22L[
M%!7!^+@9?$(0=?+11^9/]:[RN#\7+M\0J3T:.,\G'<C^E73^(3,>[ADA1/-)
M3)QD@\#CG]>U6]-N,S-*[^8YDW;P,9QWQ5>Z*HL;1O'E&!XRV.ASSQVIUNOF
M13M#(KR"0XDVX!&1D[?I6N(NT$3NTP\4D0.#*NT$]`>U0P"*/='=LQ8-M\L'
M@'KT^E9MCJ4?V-//E0R#CTSZ47'V;5Q'(S+%=`A`K#=Y@[?0]<5RIV*:N7Q<
MRP@)M)5CQE<GH?Z5`98I@"9G5@PZKQV'3MVK+$8C`C$LB1DLNP$`;AUXS@9!
MI;2V_?*8)IG("N&=@R@$YR?U]Z=R6B\]Q#!-)#)+(&4@C:,\$?2I#=0&U=8Y
MU>1ADDGKZ#\!_6LJW:.]U&XEG<I&S%5'.6Q_@*NRZ9`+4.JOOZY!SQ2=V-*Q
MDZDWEQQ,)S$0^&=1N(4@@\5GV;PK;C>BNV3C.[T&.AZ=:LWI%O/%OD,6'!$@
M7=@>N*K6JJT6YC$6)R?,)''MBNK#BD;/@V0)K<JC[KPMQ_P)<?S-=U7">#HP
M^N2,,[5A8Y_X$N/Y5W=8U/B&@KDO'-H?]%O%'`S$Q_5?Y'\ZZVJFJ62ZAITU
MJV/G7Y3Z,.0?SQ2B[.X'G$\WG*0JJJ'G`49_/K2V-S,ER`KAY)5\MLC:%].>
MG2HXSY4CQS1'<,J5)P5;H?R--SMPKF0PD@NB-@MC./RS774CS1NB5H;[6,AB
M7R_-#+SC@[C^?7-5S=SJ,"X"2(PPI&""..?UJUIVK,T)CE(:5(OFVKG_`/4?
M\:6VD:XG8S[%R1MW`*3D=ABN!Z;FA/;Z@5_UJ1F8C<SJ1EB>.WX5+<2M=PN`
M)1&H;**,.Q'8'M4EF+*9S!-;P'!(+A0N<'@\4NH):VFV&*V6,OT*Q[ORSC/.
M*-Q%2:.RAC518,^V+>%7.[D],=SUHN&5I%"JWSGD%R,?A6A;V/EGSIS&#MP-
MRE?_`$(5C:Q-`(76$,)F'REU`X)QP>?3%*S>B'<RM4F!N&6%F0*"@95X?/WA
MGVJ.&<PH02=O7&>_\JASN)V[UCR2B.V[;GK3I,S2I'!%\S84(#G<W0?F:]"G
M%0A<S;NSJO`UJ5ANKMAPY$:^^W))_,X_"NKJKIMFMA80VJ8Q&N"?4]2?Q.35
MJN.3N[E!1112`Y;Q9H9F!U&T0F11^^11]X#^(#U'ZCZ5R?FF2-$.,+TP!W]^
M]>JUR^N^%A<,]SIP5)3RT/16/J#V/Z'VK>E5Y=&)HR-+O8;`R03*$=C@RK\P
M(]#U_3\16Y,D%Q;+)`X16W<H`R`<\9SW`_\`K<BN-*M#.8KA&C93AU(PR_A5
MV"?-QYEO(T1*;W,9(P<8QQVS_.G4H*;O!@I6W-A[*8VN(#;ER?E?<1D9[C`_
MS]*?:::19;[MU-VTAZ.2B*"!@#\1U'>LZ/5;Q5<%E;RB,B2)<@=SQCO_`#I3
MJUZR0DRI&DC_`#^7&`5)[\YZC^1K+V%1=/Q'S(U_(@AA$LK@IC.YP%4#Z=SZ
M9_*L?4[Z&^"6T"J[Y_US_*![+[?6J4TA,X>[=I'PP82L3@\]/2JH5IIUAMD>
M1G.$7'S'\*UA147>;$W?80RF.-D!`#=>G;WKKO">AF`#4+M")6'[I&'*@_Q$
M>I_0?4T:%X6%NR76H[7E'S+#U"GU)[G]![UU%*K5YM$"04445@,****`"BBB
M@"M>6-K?1[+J!)1T!8<CZ'J/PKG[OP7`Q+6=T\7^S*N\?GP?SS74T4U)K8#A
M9/"&IQD[)K=P>^]AG\-IHC\):I)]^:!5XSF1S^FT5W5%5[206.5M/!<*G=>7
M;R_[,2[!^?)_+%=#9V%I8ILM8$B'<@<GZGJ?QJS14N3>X!1112`****`/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
